- Home
- ACCS vs LTRN Comparison
ACCS vs LTRN Comparison
Compare ACCS & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- LTRN
- Stock Information
- Founded
- ACCS 1988
- LTRN 2013
- Country
- ACCS United States
- LTRN United States
- Employees
- ACCS N/A
- LTRN N/A
- Industry
- ACCS Publishing
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- ACCS Consumer Discretionary
- LTRN Health Care
- Exchange
- ACCS Nasdaq
- LTRN Nasdaq
- Market Cap
- ACCS 42.6M
- LTRN 49.9M
- IPO Year
- ACCS N/A
- LTRN 2020
- Fundamental
- Price
- ACCS $9.43
- LTRN $3.98
- Analyst Decision
- ACCS Strong Buy
- LTRN Strong Buy
- Analyst Count
- ACCS 1
- LTRN 1
- Target Price
- ACCS $14.00
- LTRN $25.00
- AVG Volume (30 Days)
- ACCS 7.8K
- LTRN 164.4K
- Earning Date
- ACCS 11-11-2025
- LTRN 11-14-2025
- Dividend Yield
- ACCS N/A
- LTRN N/A
- EPS Growth
- ACCS N/A
- LTRN N/A
- EPS
- ACCS N/A
- LTRN N/A
- Revenue
- ACCS $22,562,000.00
- LTRN N/A
- Revenue This Year
- ACCS $0.03
- LTRN N/A
- Revenue Next Year
- ACCS $11.45
- LTRN N/A
- P/E Ratio
- ACCS N/A
- LTRN N/A
- Revenue Growth
- ACCS 26.44
- LTRN N/A
- 52 Week Low
- ACCS $7.79
- LTRN $2.55
- 52 Week High
- ACCS $13.35
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- ACCS 32.67
- LTRN 44.77
- Support Level
- ACCS $9.40
- LTRN $3.89
- Resistance Level
- ACCS $9.99
- LTRN $4.28
- Average True Range (ATR)
- ACCS 0.40
- LTRN 0.32
- MACD
- ACCS -0.03
- LTRN -0.04
- Stochastic Oscillator
- ACCS 3.26
- LTRN 22.85
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.